(Q57178723)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

title

Tau-targeting therapies for Alzheimer disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Einar M Sigurdsson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

Erin E Congdon

series ordinal

1

0 references

Einar M Sigurdsson

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 July 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

399-415

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

2016 Alzheimer's disease facts and figures

31 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Differential regulation of dynein and kinesin motor proteins by tau

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Multiple-motor based transport and its regulation by Tau.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Epidemiological pathology of Tau in the ageing brain: application of staging for neuropil threads (BrainNet Europe protocol) to the MRC cognitive function and ageing brain study

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Acetylation of tau inhibits its degradation and contributes to tauopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Neuropathological stageing of Alzheimer-related changes

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Frequency of stages of Alzheimer-related lesions in different age categories

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau oligomers and aggregation in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The importance of tau phosphorylation for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau cleavage and tau aggregation in neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Deregulated Cdk5 activity is involved in inducing Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Recent developments of protein kinase inhibitors as potential AD therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The Role of Cdk5 in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Protein phosphatase 2A dysfunction in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau in physiology and pathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The role of caspase cleavage of tau in Alzheimer disease neuropathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Roles of tau protein in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Caspase-2 cleavage of tau reversibly impairs memory

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Truncated tau deregulates synaptic markers in rat model for human tauopathy.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease.

2 references

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

12 December 2020

Posttranslational modifications of α-tubulin in alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau is essential to beta -amyloid-induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau reduction prevents Abeta-induced defects in axonal transport.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Metabolic states following accumulation of intracellular aggregates: implications for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The role of tau oligomers in the onset of Alzheimer's disease neuropathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Biomarkers in frontotemporal lobar degenerations--progress and challenges

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau oligomers impair artificial membrane integrity and cellular viability

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Propagation of Tau aggregates

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Autophagy in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The role of autophagy in neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Amyloid-β suppresses AMP-activated protein kinase (AMPK) signaling and contributes to α-synuclein-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Degradation of tau protein by autophagy and proteasomal pathways

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Ubiquitin is a component of paired helical filaments in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord Injury

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Protein homeostasis, aging and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Protein misfolding in neurodegenerative diseases: implications and strategies

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Knocking down disease: a progress report on siRNA therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Memantine for the treatment of frontotemporal dementia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Mechanism of CDK5/p25 binding by CDK inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Cell cycle activation and spinal cord injury

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The history and future of targeting cyclin-dependent kinases in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A phase II trial of tideglusib in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A molecular mechanism for the effect of lithium on development

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Clinical development of curcumin in neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

REVIEW: Curcumin and Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Developing therapeutic vaccines against Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68-71) improves spatial memory in okadaic acid induced tauopathy model rats.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Trans-cellular propagation of Tau aggregation by fibrillar species

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau passive immunization inhibits not only tau but also Aβ pathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Human secreted tau increases amyloid-beta production

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau immunotherapy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Mechanisms of protein seeding in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Antibody-derived in vivo imaging of tau pathology

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Evidence for neuronal expression of functional Fc (epsilon and gamma) receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Infectivity of amyloid diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

1 reference

7 January 2021

Anti-tau antibody reduces insoluble tau and decreases brain atrophy

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Harnessing the immune system for treatment and detection of tau pathology.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Alzheimer disease therapy--moving from amyloid-β to tau.

1 reference

https://api.crossref.org/works/10.1038%2FS41582-018-0013-Z

7 January 2021

Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.

1 reference

12 December 2020

Phosphorylation affects the ability of tau protein to promote microtubule assembly.

1 reference

12 December 2020

[Valve of symptomatic therapy with memantine in cerebral coma. I. Correlation with coma stages and EEG spectral patterns]

1 reference

12 December 2020

[Valve of symptomatic therapy with memantine in cerebral coma. II. Development of stretch synergisms in coma with brain stem symptoms]

1 reference

12 December 2020

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments

1 reference

12 December 2020

The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice

1 reference

12 December 2020

Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease

1 reference

12 December 2020

Lessons from tau-deficient mice

1 reference

12 December 2020

Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease

1 reference

12 December 2020

The role of extracellular Tau in the spreading of neurofibrillary pathology.

1 reference

12 December 2020

New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease.

1 reference

12 December 2020

c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease

1 reference

12 December 2020

10.1038/S41582-018-0013-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29895964%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference